Recursion falls on mixed mid-stage study data for rare disorder drug

Recursion Pharmaceuticals

03/09/2024 15:09

** Shares of Nvidia-backed Recursion Pharmaceuticals
 RXRX.O  fall 9.7% to $6.58 in morning trade
    ** Drug developer says its experimental drug to treat a rare
brain-related condition was safe and tolerable in a mid-stage
study
    ** The drug, REC-994, was being tested to treat cerebral
cavernous malformation, or abnormal collection of small blood
vessels that form lesions and cause bleeding in the brain,
seizures and paralysis
    ** While the highest dose of REC-994 displayed signs of
reduced number of lesions in the study, improvements as reported
by patients or doctors were not yet seen at the end of 12-month
treatment period - RXRX
    ** YTD, stock down 36.1%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))